Enlivex Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2012
Selling, General & Admin	6.14	7.1	6.41	3.7	3.02	1.29	0.48	0.79	6.95	2.64	Upgrade
Research & Development	19.01	18.69	12.88	6.09	5.6	4.01	1.69	2.03	7.69	4.44	Upgrade
Other Operating Expenses	4.24	0	0	0	0	0	0	0	0.83	0	Upgrade
Operating Expenses	29.4	25.8	19.29	9.79	8.62	5.3	2.17	2.82	15.48	7.08	Upgrade
Operating Income	-29.4	-25.8	-19.29	-9.79	-8.62	-5.3	-2.17	-2.82	-15.48	-7.08	Upgrade
Interest Expense / Income	-0.33	5.26	-4.82	0	0	0	0.37	0.09	0	0	Upgrade
Other Expense / Income	-	-	-	2.04	0.77	-1.06	-0.04	-0.03	-0.14	-0.06	Upgrade
Pretax Income	-29.07	-31.06	-14.47	-11.82	-9.38	-4.24	-2.5	-2.88	-15.34	-7.02	Upgrade
Income Tax	0	0	0	0	0	0	0	0	0.02	0	Upgrade
Net Income	-29.07	-31.06	-14.47	-11.82	-9.38	-4.24	-2.5	-2.88	-15.37	-7.02	Upgrade
Shares Outstanding (Basic)	19	18	18	13	9	4	3	3	0	0	Upgrade
Shares Outstanding (Diluted)	19	18	18	13	9	4	3	3	0	0	Upgrade
Shares Change	0.98%	3.00%	35.62%	52.25%	146.47%	2.43%	2.03%	843.79%	16.08%	45.55%	Upgrade
EPS (Basic)	-1.56	-1.69	-0.81	-0.90	-1.11	-1.40	-0.94	-1.03	-43.20	-22.80	Upgrade
EPS (Diluted)	-1.56	-1.69	-0.81	-0.90	-1.11	-1.40	-0.94	-1.03	-43.20	-22.80	Upgrade
Free Cash Flow	-23.63	-32.08	-19.17	-12.03	-7.23	-3.62	-2.43	-2.37	-13.3	-4.47	Upgrade
Free Cash Flow Per Share	-1.27	-1.74	-1.07	-0.91	-0.84	-1.03	-0.71	-0.71	-37.38	-14.59	Upgrade
EBITDA	-28.56	-25.02	-18.74	-11.54	-9.01	-4.12	-2.05	-2.73	-15.32	-7.02	Upgrade
Depreciation & Amortization	0.84	0.78	0.55	0.29	0.37	0.12	0.08	0.06	0.02	0.01	Upgrade
EBIT	-29.4	-25.8	-19.29	-11.82	-9.38	-4.24	-2.13	-2.79	-15.34	-7.02	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).